Midostaurin
- TRADE NAME: Rydapt (Novartis)
- INDICATIONS: Aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, or mast cell leukemia; acute myeloid leukemia (FLT3 mutation-positive) in combination with cytarabine and daunorubicin induction and cytarabine consolidation
- CLASS: Multikinase inhibitor
- HALF-LIFE: 21 hours
FDA APPROVAL DATE: 04/28/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Boceprevir, Carbamazepine, Clarithromycin, Cobicistat, Conivaptan, Danoprevir, Diltiazem, Elvitegravir, Enzalutamide, Grapefruit Juice, Idelalisib, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Mitotane, Nefazodone, Nelfinavir, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Stong CYP3A inducers and inhibitors, Tipranavir, Troleandomycin, Voriconazole
PREGNANCY CATEGORY: N/A
May cause fetal toxicity based on findings in animal studies
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric